Autopsy report · NCT00737594

Efficacy and Safety of Cobiprostone in Patients With Portal Hypertension

“Failure to enroll a suitable number of qualified subjects.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 8 months before it stopped.
• 9 participants enrolled.
• Results were posted on the registry 7 years after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Sucampo Pharma Americas, LLC

Sponsor type

Industry

Conditions

Portal Hypertension

Interventions

Placebo; Cobiprostone

Participants

9

Sites

1

Countries

United States

Trials that died the same way

• Orthopedic Study of the Aircast StabilAir Wrist Fracture Brace
  “Inability to enroll subjects” (82% match in meaning)
• Prospective Evaluation of Symptom Resolution in Acid Versus Non-acid Reflux Disease Following Anti-reflux Surgery
  “Unable to recruit a sufficient number of subjects.” (81% match in meaning)
• Augmented Reality Heads-up Display to Improve Ultrasound Guided IV Access
  “Unable to enroll subjects.” (79% match in meaning)
• The Effect of Macugen in Patients With Chronic, Post-Operative Cystoid Macular Edema
  “Difficulty enrolling eligible subjects” (79% match in meaning)
• Evaluation of Dextenza in Patients With Ocular GVHD and Effects on Ocular Surface Disease Outcomes
  “Due to difficulty enrolling subjects whom had not meet the inclusion criteria” (79% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.